Long non-coding RNA LINC00243 promotes proliferation and glycolysis in non-small cell lung cancer cells by positively regulating PDK4 through sponging miR-507

被引:0
作者
Xuegang Feng
Shengsheng Yang
机构
[1] 900 Hospital of the Joint Logistics Team,Department of Cardio Thoracic Surgery
来源
Molecular and Cellular Biochemistry | 2020年 / 463卷
关键词
LINC00243; miR-507; PDK4; Proliferation; Glycolysis; NSCLC;
D O I
暂无
中图分类号
学科分类号
摘要
Non-small cell lung cancer (NSCLC) is the main subtype of lung cancer. The overall survival of NSCLC patients is relatively low even after various treatments. Accumulating evidence demonstrated that long non-coding RNA (LncRNA) plays crucial roles in different biological process. However, the role of a novel LncRNA, LINC00243, in NSCLC remains unclear. We aimed to explore the biological role of LINC00243 in NSCLC. The mRNA and protein levels were determined by real-time PCR and western blot, respectively. Cell viability in vitro was detected by Cell Counting Kit-8 (CCK-8) assay and colony-formation assay. Reporter assay was used to detect the interactions between molecules, and the interaction was assessed by RNA pull-down assay. LINC00243 expression increased in human NSCLC tissues and associated with poor prognosis of NSCLC patients. LINC00243 knockdown inhibited proliferation and glycolysis of NSCLC cells. Mechanically, LINC00243 acted as a molecular sponge for miR-507, and miR-507 reversed the effect of LINC00243 on promoting proliferation and glycolysis of NSCLC cells. Moreover, LINC00243 modulated expression of endogenous miR-507-targeted PDK4. LINC00243 promotes proliferation and glycolysis in NSCLC cells by positively regulating PDK4 through sponging miR-507. LINC00243 could be the potential target for NSCLC treatment clinically.
引用
收藏
页码:127 / 136
页数:9
相关论文
共 131 条
  • [1] Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
  • [2] Miller KD(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
  • [3] Jemal A(2016)Non-small cell lung cancer: current treatment and future advances Transl Lung Cancer Res 5 288-300
  • [4] Bray F(2008)Lung cancer N Engl J Med 359 1367-1380
  • [5] Ferlay J(2017)Targeting lung cancer stem cells: research and clinical impacts Front Oncol 7 80-114
  • [6] Soerjomataram I(2016)Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake? Transl Lung Cancer Res 5 110-642
  • [7] Siegel RL(2016)FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy Oncologist 21 634-308
  • [8] Torre LA(2016)Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study Lancet Oncol 17 299-119
  • [9] Jemal A(2016)Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res 5 115-355
  • [10] Zappa C(2013)Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol 230 350-1214